Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis
暂无分享,去创建一个
[1] A. Albanese,et al. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: Behavioural, morphological and biochemical correlates , 1993, Neuroscience.
[2] L. Iversen. Inhibition of catecholamine uptake by 6-hydroxydopamine in rat brain. , 1970, European journal of pharmacology.
[3] W. Bender,et al. A Drosophila model of Parkinson's disease , 2000, Nature.
[4] R. Krüger,et al. The role of alpha-synuclein gene multiplications in early-onset Parkinson's disease and dementia with Lewy bodies. , 2005, Journal of neural transmission.
[5] E. Bézard,et al. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey , 1997, Brain Research.
[6] P. Bertolucci,et al. Chronic exposure to the fungicide maneb may produce symptoms and signs of CNS manganese intoxication , 1988, Neurology.
[7] Todd B. Sherer,et al. Chronic systemic pesticide exposure reproduces features of Parkinson's disease , 2000, Nature Neuroscience.
[8] A. Carlsson,et al. 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists , 1957, Nature.
[9] J. Langston. MPTP neurotoxicity: an overview and characterization of phases of toxicity. , 1985, Life sciences.
[10] C. Marsden,et al. Further treatment with MPTP does not produce parkinsonism in marmosets showing behavioural recovery from motor deficits induced by an earlier exposure to the toxin , 1989, Neuropharmacology.
[11] W. Nicklas,et al. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. , 1985, Life sciences.
[12] E. Richfield,et al. Developmental pesticide exposures and the Parkinson's disease phenotype. , 2005, Birth defects research. Part A, Clinical and molecular teratology.
[13] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[14] N. Uretsky,et al. EFFECTS OF 6‐HYDROXYDOPAMINE ON CATECHOLAMINE CONTAINING NEURONES IN THE RAT BRAIN , 1970, Journal of neurochemistry.
[15] O. Isacson,et al. Parkinson's disease: interpretations of transplantation study are erroneous , 2001, Nature Neuroscience.
[16] F. Hefti,et al. Potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium: Selective toxicity of 1-methyl-4-(4′-acetamidophenyl)-pyridinium and 1-methyl-4-cyclohexylpyridinium for dopaminergic neurons in culture , 1990, Experimental Neurology.
[17] S. Udenfriend,et al. 2,4,5-TRIHYDROXYPHENETHYLAMINE, A NEW METABOLITE OF 3,4-DIHYDROXYPHENETHYLAMINE , 1959 .
[18] David Blum,et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease , 2001, Progress in Neurobiology.
[19] D. Perl,et al. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease , 2004, Annals of neurology.
[20] S. Udenfriend,et al. Chemical, Enzymatic and Metabolic Studies on the Mechanism of Oxidation of Dopamine1 , 1959 .
[21] G. Corsini,et al. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. , 1995, European journal of pharmacology.
[22] S. W. Ranson,et al. CATALEPSY CAUSED BY LESIONS BETWEEN THE MAMMILLARY BODIES AND THIRD NERVE IN THE CAT , 1932 .
[23] O. Hornykiewicz,et al. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia]. , 1961, Wiener klinische Wochenschrift.
[24] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.
[25] J. Delay,et al. Neuroleptic effects of chlorpromazine in therapeutics of neuropsychiatry. , 1955, International record of medicine and general practice clinics.
[26] S. Totterdell,et al. Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment , 2001, Neuroscience.
[27] N Vanacore,et al. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). , 1994, Scandinavian journal of work, environment & health.
[28] C. Olanow,et al. Fetal nigral transplantation as a therapy for Parkinson's disease , 1996, Trends in Neurosciences.
[29] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[30] E. Richfield,et al. Developmental Pesticide Models of the Parkinson Disease Phenotype , 2005, Environmental health perspectives.
[31] E. Richfield,et al. A Fetal Risk Factor for Parkinson’s Disease , 2004, Developmental Neuroscience.
[32] P. Carvey,et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain , 2002, Movement disorders : official journal of the Movement Disorder Society.
[33] E. Richfield,et al. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. , 2002, Neurotoxicology.
[34] F. Fazio,et al. Striatal dopaminergic denervation in early and late onset Parkinson's disease assessed by PET and the tracer [11C]FECIT: preliminary findings in one patient with autosomal recessive parkinsonism (Park2) , 2002, Neurological Sciences.
[35] P. Carvey,et al. Prenatal exposure to the bacteriotoxin lipopolysaccharide leads to long-term losses of dopamine neurons in offspring: a potential, new model of Parkinson's disease. , 2003, Frontiers in bioscience : a journal and virtual library.
[36] Montagu Ka. Catechol Compounds in Rat Tissues and in Brains of Different Animals , 1957 .
[37] F. Cicchetti,et al. Cell implantation therapies for Parkinson's disease using neural stem, transgenic or xenogeneic donor cells. , 2001, Parkinsonism & related disorders.
[38] J. Perlmutter,et al. Prevalence of parkin gene mutations and variations in idiopathic Parkinson's disease. , 2005, Parkinsonism & related disorders.
[39] D. Calne,et al. AETIOLOGY OF PARKINSON'S DISEASE , 1983, The Lancet.
[40] J. Poirier,et al. Comparative behavioral, biochemical and pigmentary effects of MPTP, MPP+ and paraquat in Rana pipiens. , 1985, Life sciences.
[41] R. Blakely,et al. C. elegans: a novel pharmacogenetic model to study Parkinson's disease. , 2001, Parkinsonism & related disorders.
[42] J. Kordower,et al. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism , 2005, Experimental Neurology.
[43] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[44] R. F. Shore,et al. Diorthosubstituted Polychlorinated Biphenyls in Caudate Nucleus in Parkinson's Disease , 1998, Experimental Neurology.
[45] F. Hefti,et al. Toxic effects of potential environmental neurotoxins related to 1-methyl-4-phenylpyridinium on cultured rat dopaminergic neurons. , 1989, The Journal of pharmacology and experimental therapeutics.
[46] P. Holtz,et al. Fermentativer Abbau von l-Dioxyphenylalanin (Dopa) durch Niere , 1938, Naunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie.
[47] E. Richfield,et al. Age‐related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype , 2003, The European journal of neuroscience.
[48] M. Vila,et al. The 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Mouse Model , 2003 .
[49] A. Lees,et al. Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.
[50] S. Leurgans,et al. Rotenone potentiates dopamine neuron loss in animals exposed to lipopolysaccharide prenatally , 2004, Experimental Neurology.
[51] F. Colpaert,et al. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: A possible role for the locus coeruleus in the progression of Parkinson's disease , 1991, Neuroscience.
[52] J S Rakshi,et al. Measuring the rate of progression and estimating the preclinical period of Parkinson’s disease with [18F]dopa PET , 1998, Journal of neurology, neurosurgery, and psychiatry.
[53] D B Calne,et al. Compensatory mechanisms in degenerative neurologic diseases. Insights from parkinsonism. , 1991, Archives of neurology.
[54] P. Sanberg,et al. Neural Stem Cells for Cellular Therapy in Humans , 2003 .
[55] W. Longstreth,et al. Pesticides and risk of Parkinson disease: a population-based case-control study. , 2005, Archives of neurology.
[56] R. Krüger,et al. The role of α-synuclein gene multiplications in early-onset Parkinson’s disease and dementia with Lewy bodies , 2005, Journal of Neural Transmission.
[57] A. Björklund,et al. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.
[58] C. A. Stone,et al. Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. , 1963, The Journal of pharmacology and experimental therapeutics.
[59] Bruce G. Jenkins,et al. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease , 1998, Nature Medicine.
[60] Scott T. Grafton,et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. , 1992, The New England journal of medicine.
[61] J. Jeng,et al. Environmental risk factors and Parkinson's disease , 1997, Neurology.
[62] D. R. Curtis,et al. Amino acid transmitters in the mammalian central nervous system. , 1974, Ergebnisse der Physiologie, biologischen Chemie und experimentellen Pharmakologie.
[63] O. Hornykiewicz,et al. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. , 1960, Parkinsonism & related disorders.
[64] R. Ramsay,et al. The reaction sites of rotenone and ubiquinone with mitochondrial NADH dehydrogenase. , 1994, Biochimica et biophysica acta.
[65] T. Meitinger,et al. Multiple regions of α‐synuclein are associated with Parkinson's disease , 2005, Annals of neurology.
[66] M R Franklin,et al. Toxic effects. , 1977, Science.
[67] W. Poewe,et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease , 2001, European Journal of Nuclear Medicine.
[68] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[69] L. Iversen. Neuronal uptake processes for amines and amino acids. , 1970, Advances in biochemical psychopharmacology.
[70] P. Carvey,et al. Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain , 2004, Neuroscience.
[71] E. Richfield,et al. Potentiated and preferential effects of combined paraquat and maneb on nigrostriatal dopamine systems: environmental risk factors for Parkinson’s disease? , 2000, Brain Research.
[72] Charcot foot. , 2001, Orthopedic nursing.
[73] L. Olson,et al. Neurochemical and Histochemical Characterization of Neurotoxic Effects of 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine on Brain Catecholamine Neurones in the Mouse , 1985, Journal of neurochemistry.
[74] H. Chapel,et al. CLINICAL RELEVANCE OF SPECIFIC IgG ANTIBODIES TO CARDIOLIPIN , 1989, The Lancet.
[75] Janel O. Johnson,et al. Defining the ends of Parkin exon 4 deletions in two different families with Parkinson's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[76] George C. Cotzias,et al. Modification of Parkinsonism--chronic treatment with L-dopa. , 1969, The New England journal of medicine.
[77] M. Naoi,et al. Cytotoxicity of dopamine-derived 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. , 1993, Advances in neurology.
[78] B. Wolozin,et al. Pathological proteins in Parkinson’s disease , 2007, Journal of Molecular Neuroscience.
[79] Vellareddy Anantharam,et al. Dieldrin-induced neurotoxicity: relevance to Parkinson's disease pathogenesis. , 2005, Neurotoxicology.
[80] J. Sanchez-Ramos,et al. Toxicity of Dieldrin for Dopaminergic Neurons in Mesencephalic Cultures , 1998, Experimental Neurology.
[81] Y. C. Chang,et al. Effects of paraquat on the substantia nigra of the wistar rats: neurochemical, histological, and behavioral studies. , 1996, Toxicology and applied pharmacology.
[82] G. Nisticó,et al. Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. , 1998, Pharmacology & toxicology.
[83] C. Marsden,et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. , 1999, Brain : a journal of neurology.
[84] E Bertrand,et al. Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease. , 1997, Folia neuropathologica.
[85] E. Bézard,et al. Kinetics of nigral degeneration in a chronic model of MPTP-treated mice , 1997, Neuroscience Letters.
[86] Eric K. Richfield,et al. Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice , 2004 .
[87] J. Langston,et al. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: A neurochemical and morphological reassessment , 1986, Brain Research.
[88] N. Kline,et al. Use of Rauwolfia serpentina Benth. in neuropsychiatric conditions. , 1954, Annals of the New York Academy of Sciences.